Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Common Equity of $153.3 million for Q4 2025, up 1779.11% on a QoQ basis from $8.2 million in Q3 2025, and up 11391.18% year-over-year from N/an in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Common Equity history runs 3 years deep, the most recent figure standing at $153.3 million for Q4 2025.
- Quarterly Common Equity rose 11391.18% year-over-year to $153.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153.3 million (up 11391.18% YoY) and the FY2025 annual result came in at $153.3 million, up 11391.18% from the prior year.
- Common Equity was $153.3 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $8.2 million in the prior quarter.
- Across five years, Common Equity topped out at $153.3 million in Q4 2025 and bottomed at -$1.8 million in Q1 2025.
- A 3-year average of $18.5 million and a median of -$264604.0 in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 4361.57% — and 2025, when it jumped 11391.18%.
- Apimeds Pharmaceuticals US's Common Equity stood at $31869.0 in 2023, then tumbled by 4361.57% to -$1.4 million in 2024, then soared by 11391.18% to $153.3 million in 2025.
- Business Quant data shows APUS's Common Equity at $153.3 million in Q4 2025, $8.2 million in Q3 2025, and $9.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | 153.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 153.35 Mn |
| Sep 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 9.74 Mn |
| Mar 31, 2025 | -1.76 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -713,967.00 |
| Mar 31, 2024 | -264,604.00 |
| Dec 31, 2023 | 31,869.00 |